ET-traps limited - Our technology focuses on sequestering pathologically elevated levels of Endothelin-1 in different diseases.
ET-traps Limited was incorporated in 2015 after its founder, Dr Arjun Jain won the Biotech startup weekend organized by Judge Business School in association with AstraZeneca UK.
ET-traps is a novel therapeutic for sequestering pathologically elevated endothelin-1 (ET-1) levels in the body, which is associated with a number of diseases including cardiovascular atherosclerosis, chronic kidney disease, pulmonary arterial hypertension, cancer, diabetes and neurodegenerative disorders e.g. MS.
By binding only to the excess ET-1 in the body to bring it down to normal control levels and not completely blocking the action of ET-1 in other physiological functions, ET-traps are non-toxic.
We have performed binding assays* that confirmed the solubility of our ET-trap construct and that it is a very potent binder to endothelin-1, with a binding affinity in the pico molar range.
We have also performed PoC studies* in the diabetes disease space, which show that the ET-traps potently and significantly ameliorate disease pathology and bring back various markers of heart and kidney function down to non-disease levels.
Furthermore, our PoC work (both in vitro and in vivo) has shown that ET-traps are non- toxic or cytotoxic at the working concentration, which gives an efficacious effect.
When compared to ERAs, ET-traps 1) do not have side effects since they merely sequester pathologically elevated endothelin-1 back to physiological levels instead of completely blocking its action like ERAs do 2) have lower patient dosing due to longer serum half-life and better binding affinity and 3) cost ~4.5 times less per week of patient dosage (based on our small batch manufacturing cost).
Our patent has been granted in the US and EPO and approved in Australia.